Research programme: small molecule therapeutics - Interprotein

Drug Profile

Research programme: small molecule therapeutics - Interprotein

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Interprotein Corporation
  • Class Small molecules
  • Mechanism of Action CD antigen inhibitors; Interleukin receptor antagonists; Protein-protein interaction inhibitors; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Inflammation

Highest Development Phases

  • Research Cancer; Inflammation

Most Recent Events

  • 31 Oct 2017 Research programme: small molecule therapeutics - Interprotein is available for licensing as of 31 Oct 2017. http://www.interprotein.com/program.html
  • 31 Oct 2017 Early research in Cancer in Japan (unspecified route)
  • 31 Oct 2017 Early research in Inflammation in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top